Saturday, October 24, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1semaglutideobesityweight regaintufts

Pilot trial tests two strategies against weight regain after stopping GLP-1s

Usual-care patients regained an estimated 10.75% of body weight over four months, versus about 3.6% with either a behavior app or home-delivered meals.

MH
By Maren Holt · Senior Reporter, GLP-1
Oct 7 09:54 ETSource: Drugs.com

The wire

  1. 01A pilot trial in Obesity Science & Practice followed 39 adults discontinuing GLP-1s across three arms: usual care, the Noom app, or medically tailored meals, with Bluetooth scales tracking weight for four months.
  2. 02Clinicians and telehealth operators managing GLP-1 discontinuation now have early comparative data on structured support, a recurring gap as patients cycle off treatment for cost or supply reasons.
  3. 03Sample size was 39 and follow-up only four months; the authors say larger, longer and more diverse studies are needed before the findings guide practice.

From the source

Limiting Weight Regain After GLP-1s: Two Strategies Show Promise

WEDNESDAY, Oct. 7, 2026 — What’s the best way to keep the scale from creeping back up after you stop using a GLP-1 medication? A study published today in the journal Obesity Science & Practice set out to answer this question.The pilot trial...

Read at drugs.com
PeptiPrescribed peptides from $99/moSee all →